{
    "2021-10-28": [
        [
            {
                "time": "",
                "original_text": "疫苗股午后异动，康希诺涨超4%",
                "features": {
                    "keywords": [
                        "疫苗",
                        "康希诺",
                        "涨超4%"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【券商聚焦】交银维持复星医药(02196)买入评级 指业绩稳健增长且研发进展顺利",
                "features": {
                    "keywords": [
                        "复星医药",
                        "买入评级",
                        "业绩稳健增长",
                        "研发进展顺利"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "三季度营收超100亿，复星医药抗住降价压力业绩持续增长",
                "features": {
                    "keywords": [
                        "复星医药",
                        "三季度营收",
                        "业绩持续增长",
                        "降价压力"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "纳微科技(688690)：业绩持续高增长 引进归国核心技术人才研发实力进一步增强",
                "features": {
                    "keywords": [
                        "纳微科技",
                        "业绩持续高增长",
                        "核心技术人才",
                        "研发实力增强"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "科技",
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "三个月股价腰斩，疫苗救不了复星医药",
                "features": {
                    "keywords": [
                        "复星医药",
                        "股价腰斩",
                        "疫苗"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "伴随诊断白热化，MRD检测如何能成为肿瘤NGS企业的第二曲线？",
                "features": {
                    "keywords": [
                        "伴随诊断",
                        "MRD检测",
                        "肿瘤NGS企业",
                        "第二曲线"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "信达达伯舒Q3销售额创新高；复星医药公布2021Q3财报",
                "features": {
                    "keywords": [
                        "信达达伯舒",
                        "Q3销售额创新高",
                        "复星医药",
                        "2021Q3财报"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}